Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P41250

UPID:
GARS_HUMAN

ALTERNATIVE NAMES:
Diadenosine tetraphosphate synthetase; Glycyl-tRNA synthetase; Glycyl-tRNA synthetase 1

ALTERNATIVE UPACC:
P41250; A0A090N8G0; B3KQA2; B4DIA0; Q969Y1

BACKGROUND:
Glycine--tRNA ligase, with alternative names Glycyl-tRNA synthetase 1 and Diadenosine tetraphosphate synthetase, is essential for the synthesis of proteins and the regulation of cellular pathways through its role in the ATP-dependent addition of glycine to tRNA and the production of Ap4A.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Glycine--tRNA ligase could open doors to potential therapeutic strategies for treating neuromuscular diseases such as Charcot-Marie-Tooth disease, axonal, 2D, distal hereditary motor neuronopathy, 5A, and infantile spinal muscular atrophy, James type, by targeting the underlying genetic variants.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.